Meeting
2023 ASCO Annual Meeting
The inclusion of health-related quality of life and other patient-reported outcomes in landmark trials for Food and Drug Administration oncology drug approvals: An analysis of cancer drug approvals between 2006 and 2022.
Authors
Ademola Samuel Ojo
Howard University Hospital, Washington, DC
Ademola Samuel Ojo , Ahmed Ali
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Care Delivery and Regulatory Policy
Track
Care Delivery and Quality Care
Sub Track
Clinical Research Design
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 1569)
DOI
10.1200/JCO.2023.41.16_suppl.1569
Abstract #
1569
Poster Bd #
163
Abstract Disclosures
Similar Posters
Poster
2020 Genitourinary Cancers Symposium
Trends in PRO reporting in clinical trials leading to GU cancer drug approvals from 2007 to 2018.
First Author: Monica Tamil
Poster
2024 ASCO Genitourinary Cancers Symposium
Avelumab first-line maintenance (1LM) for advanced urothelial carcinoma (aUC): Long-term patient-reported outcomes (PROs) in the phase 3 JAVELIN Bladder 100 trial.
First Author: Petros Grivas
Poster
2023 ASCO Annual Meeting
Proactive assessment of patient reported outcomes in patients with ovarian cancer.
First Author: Ainhoa Madariaga
Poster
2021 ASCO Annual Meeting
Overall survival, quality of life and magnitude of clinical benefit of breast cancer drugs over the last 25 years.
First Author: J. Carlos Tapia